Key result
Capecitabine rechallenge succeeds without recurrent Takotsubo syndrome following 5-fluorouracil-induced cardiomyopathy.
Why the study?
There is little data describing the viability of fluoropyrimidine rechallenge after fluoropyrimidine-induced Takotsubo syndrome.
Does capecitabine rechallenge prevent recurrence of symptoms in a patient with 5-fluorouracil-induced Takotsubo syndrome?
Population
1 woman with metastatic oesophageal cancer and 5-fluorouracil-induced Takotsubo syndrome
Comparison
Capecitabine rechallenge replacing 5-fluorouracil
Design
Case report
Follow-up
Remainder of chemotherapy treatment
Authors
Loading...
May support capecitabine rechallenge after 5-FU Takotsubo in select cases; single report leaves open broader safety and generalizability.
Case Report (n=1)
Does capecitabine rechallenge prevent recurrence of symptoms in a patient with 5-fluorouracil-induced Takotsubo syndrome?
This case report suggests that capecitabine rechallenge may be a safe and viable option for patients who experience 5-fluorouracil-induced Takotsubo syndrome.
Abdel‐Rahman et al. (2016) conducted a case report in Metastatic oesophageal cancer and 5-fluorouracil-induced Takotsubo syndrome (n=1). Capecitabine rechallenge was evaluated on Recurrence of symptoms. Capecitabine rechallenge was successful without recurrence of symptoms in a 41-year-old woman who had developed Takotsubo syndrome following 5-fluorouracil treatment.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: